digoxin and pimobendan

digoxin has been researched along with pimobendan* in 2 studies

Trials

1 trial(s) available for digoxin and pimobendan

ArticleYear
Intractable heart failure despite angiotensin-converting enzyme inhibitors, digoxin, and diuretics: long-term effectiveness of add-on therapy with pimobendan.
    American heart journal, 1991, Volume: 122, Issue:2

    In 25 patients whose chronic congestive heart failure (CHF) had recently worsened to New York Heart Association class IV, pimobendan (5 to 20 mg/day) was added to maximum conventional therapy consisting of digoxin, diuretics, angiotensin-converting enzyme inhibitors, coumadin derivatives to prevent thromboembolic complications, and amiodarone to suppress serious ventricular rhythm disturbances. CHF was fatal in less than 1 month in five patients (two had shown some initial improvement). The other 20 had sustained improvement by at least one functional class, interrupted by episodes of CHF that usually responded to intravenous therapy. Median survival was 12 months (range 10 days to greater than 3 years); five patients died suddenly, 12 died of intractable CHF, and two died of other causes. Six patients were alive 3 years after the onset of treatment with pimobendan. Add-on therapy with pimobendan produced a sustained improvement in many patients with severe CHF that was no longer responding to a combination of digoxin, diuretics, and angiotensin-converting enzyme inhibitors.

    Topics: Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Arrhythmias, Cardiac; Digoxin; Diuretics; Female; Heart Failure; Humans; Male; Pyridazines; Survival Analysis; Vasodilator Agents

1991

Other Studies

1 other study(ies) available for digoxin and pimobendan

ArticleYear
Canine dilated cardiomyopathy: a retrospective study of prognostic findings in 367 clinical cases.
    The Journal of small animal practice, 2010, Volume: 51, Issue:8

    To review the association between clinical signs and diagnostic findings and the survival time of dogs with dilated cardiomyopathy (DCM), and any influence of treatment prescribed.. A retrospective observational study of 367 dogs with DCM. Survival times until death or euthanasia for cardiac reasons were analysed using the Kaplan-Meier method plus univariate and multivariate Cox proportional hazards models. Two-tailed P values less than 0.05 were considered statistically significant.. In the multivariate model, left ventricular diameter (LVDs)-index (P=0.0067), presence of pulmonary oedema on radiography (P=0.043), presence of ventricular premature complexes (VPCs) (P=0.0012), higher plasma creatinine (P=0.0002), lower plasma protein (P=0.029) and great Dane breed (P=0.0003) were negatively associated with survival. Most dogs were treated with angiotensin-converting enzyme inhibitors (93%) or furosemide (86%), and many received digoxin (50%) and/or pimobendan (30%). Thirteen dogs were lost to follow-up. No conclusions could be made in this study on the association between use of drugs and survival.. The LVDs-index was the single best variable for assessing the prognosis in this group of dogs with DCM. Other variables that were negatively associated with survival were presence of pulmonary oedema on radiography, presence of VPCs, higher plasma creatinine, lower plasma protein and great Dane breed.

    Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Breeding; Cardiomyopathy, Dilated; Cardiotonic Agents; Digoxin; Dog Diseases; Dogs; Female; Furosemide; Kaplan-Meier Estimate; Male; Prognosis; Proportional Hazards Models; Pyridazines; Retrospective Studies; Treatment Outcome

2010